GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) — Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last
(Financial Post, 2025-12-12T15:35:28Z)